Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Post by Speyeder999on Jul 12, 2021 12:50pm
260 Views
Post# 33530095

Acumen Pharmaceuticals Inc

Acumen Pharmaceuticals IncThought some might be interested.....a few weeks back, I had posted something in regards with Acumen Pharma (a close competitor to Promis working on the same toxic oligomers targets) was going public in the near future .....well they did on July 1.

So the company market cap is sitting at 675M as of today with 37M shares outstanding. Not much information is disclosed on their site when compared to PROMIS, but they have initiated a Phase 1 clinical study of their lead drug (and only one from what I can see) .

So yeah, 10X more than PROMIS, but based on what? Who knows....but I hope that's where were heading in a years time!

Good luck (and patience) to all!

https://seekingalpha.com/article/4437332-acumen-pharmaceuticals-pursues-125-million-ipo
<< Previous
Bullboard Posts
Next >>